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Abstract
Background: The MCE, Momordica charantia fruit extract Linn. (Cucurbitaceae) have been documented to elicit hypoglycemic
activity on various occasions. However, due to lack of standardization of these extracts, their efficacy remains questionable. The
present study was undertaken by selecting a well standardised MCE. This study reports hypoglycemic and antilipidemic activities
of MCE employing relevant animal models and in vitro methods.
Methods: Diabetes was induced in Wistar rats by a s.c., subcutaneous injection of alloxan monohydrate (100 mg/kg) in acetate
buffer (pH 4.5). MCE and glibenclamide were administered orally to alloxan diabetic rats at doses of 150 mg/kg, 300 mg/kg &
600 mg/kg, and 4 mg/kg respectively for 30 days, blood was withdrawn for glucose determination on 0, 7, 14, 21 and 30th days.
On the 31st day, overnight fasted rats were sacrificed and blood was collected for various biochemical estimations including
glycosylated haemoglobin, mean blood glucose, serum insulin, cholesterol, triglcerides, protein and glycogen content of liver.
The hemidiaphragms and livers were also isolated, carefully excised and placed immediately in ice cooled perfusion solution and
processed to study the glucose uptake/transfer processes. Hypolipidemic activity in old obese rats was evaluated by treating two
groups with MCE (150 mg/kg & 300 mg/kg) orally for 30 days and determining total cholesterol, triglyceride and HDL-CH, LDL-
CH and VLDL-CH levels from serum samples.
Results: Subchronic study of MCE in alloxan induced diabetic rats showed significant antihyperglycemic activity by lowering
blood glucose and GHb%, percent glycosylated haemoglobin. Pattern of glucose tolerance curve was also altered significantly.
MCE treatment enhanced uptake of glucose by hemidiaphragm and inhibited glycogenolysis in liver slices in vitro. A significant
reduction in the serum cholesterol and glyceride levels of obese rats following MCE treatment was also observed.
Conclusion: Our experimental findings with respect to the mechanism of action of MCE in alloxan diabetic rats suggest that it
enhances insulin secretion by the islets of Langerhans, reduces glycogenesis in liver tissue, enhances peripheral glucose utilisation
and increases serum protein levels. Furthermore, MCE treatment restores the altered histological architecture of the islets of
Langerhans. Hence, the biochemical, pharmacological and histopathological profiles of MCE clearly indicate its potential
antidiabetic activity and other beneficial effects in amelioration of diabetes associated complications. Further, an evaluation of
its antilipidemic activity in old obese rats demonstrated significant lowering of cholesterol and triglyceride levels while elevating
HDL-cholesterol levels. Also, the extract lowered serum lipids in alloxan diabetic rats, suggesting its usefulness in controlling
metabolic alterations associated with diabetes.
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Background
The Indian system of medicine has treated diabetes with
its herbals for ages. Vegetables are among the numerous
plant adjuncts tried for the treatment of diabetes mellitus.
In recent years, there has been a renewed interest to screen
such plant food materials, especially, to examine the long-
term beneficial effect of dietary vegetables, to identify the
active principle, and to understand the mechanism of
action, which is at present unclear. Virtually, all forms of
diabetes mellitus are caused by a deficiency of insulin
secretion or by a combination of insulin resistance and
inadequate insulin secretion. Hyperglycemia is the most
consistent sign of diabetes, but is not a sensitive indicator
at the onset of the disease. GHb, glycosylated haemo-
globin is abnormally high in diabetes, with chronic hyper-
glycemia and often reflects their metabolic control [1].
Liver is an insulin dependent tissue, which plays a pivotal
role in glucose and lipid homeostasis and is severely
affected during diabetes [2]. During diabetes a profound
alteration in the concentration and composition of lipid
occurs [3]. Decreased glycolysis, impeded glycogenesis
and increased gluconeogenesis are some of the changes of
glucose metabolism in the diabetic liver. Diabetes melli-
tus is known to cause hyperlipidemia through various
metabolic derangements. Among several metabolic
derangements, insulin deficiency has been known to stim-
ulate lipolysis in the adipose tissue and give rise to hyper-
lipidemia and fatty liver. Thus, in diabetes
hypercholesterolemia and hypertriglyceridemia often
occur [4].
This paper describes the study of Momordica charantia
Linn as an antidiabetic herbal.
M. charantia also known as bittermelon or bittergourd
belongs to the family Cucurbitaceae. The hypoglycemic
activity of Momordica charantia has been observed and
documented on many occasions [5-8]. Its fruits, leaves
and stems have been extensively used and reported for its
hypoglycemic effect. Compounds isolated from the fruits
& seeds that are believed to contribute to its hypoglycemic
activity include charantin (a steroidal glycoside), vicine (a
glycoalkaloid) and polypeptide 'p' (a 166 residue insuli-
nomimetic peptide).
Momordica charantia has been hypothesized to act via both
pancreatic and extra-pancreatic mechanisms [5,6]. Vari-
ous studies on M. charantia have suggested its potential
benefit in diabetes. But a lack of proper biomarkers and
appropriate parameters for standardization of its prepara-
tions has often resulted in varied efficacy and safety. This
study was thus initiated with an aim of evaluating the
effects of a standardized MCE on blood glucose, serum
insulin, serum lipid levels, glucose uptake and glycogene-
sis in tissues of alloxan diabetic rats. It, thus, investigates
the hypoglycemic activity and probable underlying mech-
anisms of action of the extract by determining changes in
various biochemical & histopathological parameters. The
study also evaluates the hypolipidemic activity of MCE in
alloxan diabetic and old obese rats which would be bene-
ficial in the overall treatment and control of diabetes mel-
litus.
Methods
Animals
Albino rats of the Wistar strain, of either sex, weighing
150–200 g, were purchased from Bharat Sera & vaccines
Ltd., Mumbai, India and housed under standard environ-
mental conditions (temperature: 24 ± 1°C, light/dark
cycle: 10/14 h). The rats were fed with standard pellet diet
(Amrut laboratory animal feed, Maharashtra, India) and
water  ad libitum. Animals described as fasted were
deprived of food for 10 h but had free access to water. Ani-
mals described as old obese included old male albino
Wistar rats 18 months of age weighing 325–350 g, which
were maintained on the usual diet during the entire
period of study.
The institutional animal house is registered with the Govt.
of India and bears the registration No.25/1999/CPCSEA.
Experimental protocols were reviewed and approved by
the institutional animal ethics committee and conform to
the Indian National Science Academy Guidelines for the
use and care of experimental animals in research.
Source of MCE
An authentic standardized MCE was obtained from Amsar
Pvt. Ltd, Indore, India. It is an ethanolic extract which has
been further fractionated in ethyl acetate and supplied as
a 10% processed powder [Lot No: 570, May 2003]. The
preparation has been standardised and optimised at the
commercial plant of Amsar Pvt. Ltd., Indore, India.
MCE was tested for its acute and short-term toxicity in
rats. An acute dose upto 4800 mg/kg was found safe with-
out any abnormal behaviour in rats. Sub-chronic toxicity
upto dose of 1000 mg/kg was found safe and did not
show any haematological or biochemical alterations in
the rats.
Drugs and chemicals
Alloxan monohydrate was purchased from Loba Chemie,
Mumbai, India. Glibenclamide was procured from
Aventis Pharma, Mumbai, India. All other chemicals were
obtained from local sources and were of analytical grade.
Preparation of extract, reference drug and alloxan
The extract was administered orally to rats at various
doses, as a suspension in 1% w/v CMC, carboxy methyl
cellulose. glibenclamide was used as a reference drug andBMC Complementary and Alternative Medicine 2007, 7:29 http://www.biomedcentral.com/1472-6882/7/29
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was administered orally at 4 mg/kg as a suspension in 1%
w/v CMC. Alloxan was prepared at a concentration of 100
mg/ml in acetate buffer (pH 4.5).
Experimental procedure
Study of the anti-diabetic activity of MCE in hyperglycemic rats
Alloxan induced diabetes
Diabetes was induced in rats by a s.c. injection of alloxan
monohydrate 100 mg/kg in acetate buffer (pH 4.5). Six
days later, blood samples were drawn and tested for blood
glucose to confirm diabetes. The diabetic rats showing
blood glucose levels above 250 mg% were selected for the
following studies.
Glucose tolerance curve in alloxan diabetic rats
The diabetic rats were randomly divided into 5 groups of
6 animals each. Three groups received MCE at 150, 300
and 600 mg/kg, p.o. The 4th group was administered glib-
enclamide (4 mg/kg, p.o.) while the 5th group served as
diabetic control, 1% CMC (10 ml/kg, p.o.). All groups
received glucose solution (1 g/kg) 30 minutes after the
above treatments. Blood levels were determined at 0.5,
1.5 and 2 h after glucose administration.
Estimation of biochemical parameters
A group of 32 diabetic rats overnight fasted were ran-
domly divided into 4 groups (8 rats/group) and treated
orally with 1% CMC (10 ml/kg), MCE (150 mg/kg and
300 mg/kg) and glibenclamide (4 mg/kg) each, prior to
food. Another group of 8 normal healthy rats was used as
a normal control. The treatments were continued for 30
days. Effect of MCE (300 mg/kg) and glibenclamide at (4
mg/kg) on normal rats for 30 days was also carried out to
see per se effect. Blood glucose levels were determined on
different days viz. 0, 7th, 14th, 21st and 30th day (24 h after
the previous dose) by collecting blood from tail vein. On
the 31st day, overnight fasted rats were sacrificed and
blood was collected for various biochemical estimations.
GHb% was determined in heparinised whole blood by
ion exchange resin method [9] using commercial kit from
Vector Biotek Pvt Ltd, Gujarat, India. Further, the HbA1c
fraction and mean blood glucose were calculated from the
GHb%. Serum insulin was determined by insulin micro-
plate ELISA technique using a commercial kit from
Monobind Inc, CA, USA. Total cholesterol was deter-
mined in serum using a commercial kit from Biolab Diag-
nostics, India [10]. Serum triglycerides were determined
using a commercial kit from Transasia Bio-Medicals Ltd,
India [11]. Total protein was determined in the serum by
the method of Lowry et al [12]. The liver was homoge-
nized in 5 % w/v trichloroacetic acid and its glycogen con-
tent was determined by the method of Caroll et al [13].
Effect on glucose uptake by hemidiaphragm and liver glycogenolysis
The hemidiaphragms and livers of rats treated daily for 30
days as described above were isolated after sacrificing
under ether anaesthesia. The tissues were carefully excised
and placed immediately in ice cooled perfusion solution
with the following composition: NaCl (0.687%), KCl
(0.04%), MgSO4  (0.014%), CaCl2  (0.028%), NaHPO4
(0.014%) and NaHCO3 (0.21%). Glucose was added to
another batch of the perfusate at a concentration of 400
mg%. This perfusate was used to study the glucose uptake/
transfer processes. The hemidiaphragms were incubated
at 37°C for 1.5 h with appropriate aeration to enable stir-
ring and also to provide oxygen to the tissue. At the end of
the incubation period glucose concentration in the per-
fusate was assayed. The diaphragms were removed, rinsed
in water and dried in an oven at 55–60°C for 4–5 h or till
a constant weight was obtained. The glucose uptake dur-
ing the incubation period was calculated in terms of mg/
100 mg dry weight of diaphragm. Similarly, liver slices
were incubated in the glucose enriched perfusate. The glu-
cose concentration in the perfusate after the incubation
period was determined in terms of mg/g of dry weight of
liver.
Histopathological study of pancreas of alloxan diabetic rats
The pancreas of 4 groups of alloxan diabetic rats treated
with MCE (150 mg/kg and 300 mg/kg), glibenclamide (4
mg/kg) and 1% CMC (10 ml/kg) respectively, for a period
of 30 days and one group of normal control rats were iso-
lated and preserved in 10%(v/v) formalin. Histopatholog-
ical evaluation of the tissues [14] was carried out at
clinico-pathology laboratory, Haffkine Institute, Mumbai,
India. The histological effects were transformed into
numerical scoring system and finally expressed in terms of
mean ± SEM
Evaluation of hypolipidemic activity of MCE in old obese rats
A group of 24 old obese male albino Wistar rats [14] were
divided into 3 groups of 8 animals each. The groups
received the following treatments daily for 30 days. Group
A served as a control and received only 1% w/v CMC sus-
pension. Group B and C received MCE orally at 150 and
300 mg/kg respectively. On the 31st day overnight fasted
rats were weighed, sacrificed under ether anesthesia and
their blood was collected by cardiac puncture for serum
separation. The sera were collected by centrifugation of
the clotted blood at 2500 rpm at 30°C for 15 min. The
serum samples were used for the determination of total
cholesterol, triglyceride and HDL-CH levels using com-
mercial kits as described earlier. Further, LDL-CH and
VLDL-CH levels were calculated from the data obtained.
Statistical analysis
The results were expressed as Mean ± SEM. The data
obtained was subjected to statistical analysis using one-BMC Complementary and Alternative Medicine 2007, 7:29 http://www.biomedcentral.com/1472-6882/7/29
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way ANOVA followed by Dunnett's post test for compari-
son between control and test groups. A 'p' value < 0.05 was
considered to be significant.
Results
Studies in diabetic rats
a) Glucose tolerance curve in alloxan diabetic rats
MCE/glibenclamide treatment significantly inhibited the
rise in blood sugar levels in glucose loaded rats. The
extract at 300 mg/kg showed an effect equivalent to that
of glibenclamide (4 mg/kg). As the inhibitory effect of
MCE (600 mg/kg) was comparable to that of 300 mg/kg,
it was considered that MCE (300 mg/kg) may be the ceil-
ing dose (Figure 1) for its inhibitory effect.
b) Estimation of biochemical parameters
Alloxan diabetic rats showed significant elevation in the
blood glucose, glycosylated hemoglobin and serum lipid
levels while the serum insulin, total protein and liver gly-
cogen levels were decreased significantly in comparison to
normal rats. Administration of MCE and glibenclamide
restored the above parameters significantly towards nor-
mal. The effect of MCE (300 mg/kg) body weight was
more significant than that of 150 g/kg and was compara-
ble with that of glibenclamide (4 mg/kg).
The extract elicited a hypoglycemic effect in alloxan
induced diabetic rats as observed by the decrease in blood
glucose levels determined on various days during the
study (Figure 2). The initial blood glucose levels of the
diabetic rats selected for the study were in the range of
260–290 mg%. In the untreated group, the blood glucose
further increased to 295.5 mg% on the 30th day. In the
diabetic rats treated with MCE (150 mg/kg and 300 mg/
kg), the blood glucose levels decreased steadily to 192.0
mg% and 152.4 mg% respectively, on the 30th day. Glib-
enclamide (4 mg/kg) lowered the blood glucose levels to
142.8 mg% following a 30 day treatment. The effect of
MCE (300 mg/kg) was comparable to that of glibencla-
mide while that of MCE (150 mg/kg) was lower.
Treatment with MCE reduced percent GHb levels from
10.1% (in diabetic control) to 8.0% and 8.1% in rats
treated with 300 mg/kg and 150 mg/kg doses respectively.
The GHb levels were found to be 7.8% in glibenclamide 4
mg/kg treated rats (Figure 3).
Insulin levels were found to be much lower (1.6 µIU/ml)
in the alloxan diabetic untreated rats when compared
with the nondiabetic control (3.5 µIU/ml) group. Treat-
ment with MCE as well as glibenclamide significantly ele-
vated the insulin levels (Table 1).
The diabetic rats showed elevated levels of serum choles-
terol, triglycerides and decreased total protein levels. Fol-
lowing treatment with MCE (300 mg/kg) or
glibenclamide (4 mg/kg), cholesterol, triglyerides and
protein levels were restored to nearly normal (Table 1).
Effect of Momordica charantia extract on the glucose toler- ance of alloxan diabetic rats Figure 1
Effect of Momordica charantia extract on the glucose 
tolerance of alloxan diabetic rats. Values are mean ± 
SEM from 6 animals in each group. Significant difference of 
diabetic control from normal control :#P < 0.001. Significant 
difference of treated groups from diabetic control on the 
corresponding time intervals: aP < 0.001, bP < 0.005, cP < 
0.01, dP < 0.05.
Effect of Momordica charantia extract on the blood glucose  levels of alloxan diabetic rats on various treatment days Figure 2
Effect of Momordica charantia extract on the blood 
glucose levels of alloxan diabetic rats on various 
treatment days. Values are mean ± SEM. N = number of 
animals in each group. Significant difference of diabetic con-
trol from normal control: #P < 0.001. Significant difference of 
treated groups from diabetic control on the corresponding 
days: aP < 0.001, bP < 0.005, cP < 0.01, dP < 0.05.BMC Complementary and Alternative Medicine 2007, 7:29 http://www.biomedcentral.com/1472-6882/7/29
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There was a marked reduction in the liver glycogen levels
of alloxan diabetic rats from 3.8 g/100 g tissue (in normal
control rats) to 0.84 g/100 g tissue. MCE (150 mg/kg)
treatment showed 72.6% increase while at 300 mg/kg
there was 100% increase in liver glycogen levels as com-
pared with the untreated diabetic rats. Glibenclamide
treatment elicited 98.8% increase in liver glycogen levels
when compared to the untreated diabetic rats (Table 2).
Treatment with MCE (300 mg/kg) and glibenclamide (4
mg/kg) for 30 days elicited insignificant changes in all
biochemical parameters assayed. Hence results are not
shown in the table.
c) Effect on glucose uptake by hemidiaphragm and glycogenolysis by 
the liver
Hemidiaphragms taken from rats treated with MCE and
glibenclamide showed a significant enhancement of the
glucose uptake process as compared to diabetic untreated
rats. Also, both MCE and glibenclamide treated rats
showed a significant inhibitory effect on glycogenolysis in
liver slices (Table 2).
d) Histopathological study of the pancreas of alloxan diabetic rats
The normal control rats showed no architectural changes
in the histology of the pancreas. In the alloxan diabetic
untreated rats, the islets of Langerhans showed diffused
necrotic changes of moderate to marked degree as a result
of which they were significantly reduced in size and
number. Only occasional presence of the islets could be
detected in a few rats. The group of rats treated with glib-
enclamide showed diffused necrotic changes of mild to
moderate degree in the pancreas. There was a mild reduc-
tion in the size and number of the islets in this group. The
effect of MCE (150 mg/kg) on alloxan diabetic rats was
comparable with that of glibenclamide. The MCE (300
mg/kg) treated group of rats showed mild to moderate
degree of necrosis of the islets of Langerhans. The pancre-
atic damage observed in glibenclamide and MCE (150
mg/kg) treated diabetic animals was milder than that
found in the untreated diabetic control group. Pancreas of
MCE (300 mg/kg) treated rats showed milder damage in
comparison to that observed in the glibenclamide and
MCE (150 mg/kg) treatment groups. (Table 2).
Hypolipidemic effect of MCE in old obese rats
The old obese rats selected for the study had elevated
serum lipid levels. Following 30 days treatment with MCE
at 150 & 300 mg/kg doses, the rats showed dose depend-
ent reduction in cholesterol, triglyceride, LDL-CH, VLDL-
CH and blood glucose levels as compared to untreated
Effect of Momordica charantia extract on glycosylated hemo- globin levels (GHb%) and HbA1c fraction of alloxan diabetic  rats Figure 3
Effect of Momordica charantia extract on glyco-
sylated hemoglobin levels (GHb%) and HbA1c frac-
tion of alloxan diabetic rats. Values are mean ± SEM from 
8 animals in each group. Significant difference of diabetic con-
trol from normal control: #P < 0.001. Significant difference of 
treated groups from diabetic control on the corresponding 
days: aP < 0.001.
Table 1: Effect of Momordica charantia extract on the serum insulin, cholesterol, triglyceride and total protein levels of alloxan diabetic 
rats
Oral treatment Insulin µIU/ml (n = 6) Cholesterol mg% (n = 8) Triglycerides mg % (n = 8) Protein g% (n = 8)
Mean ± SEM
Normal control 3.5 ± 0.4 78.8 ± 0.8 58.3 ± 0.4 7.7 ± 0.1
Diabetic control 1.6 ± 0.2# 109.6 ± 1.2# 117.1 ± 2.8# 6.0 ± 0.1#
MCE (150 mg/kg) 2.2 ± 0.3 92.2 ± 2.3a 100.3 ± 1.6a 7.1 ± 0.2a
MCE (300 mg/kg) 2.6 ± 0.3c 78.0 ± 1.6a 97.8 ± 2.6a 7.4 ± 0.4a
Glibenclamide (4 mg/kg) 2.7 ± 0.2a 81.5 ± 1.0a 93.2 ± 2.3a 7.5 ± 0.3a
Significant difference of diabetic control from normal control : #P < 0.001
Significant difference of treated groups from diabetic control on the corresponding days: aP < 0.001, cP < 0.01.BMC Complementary and Alternative Medicine 2007, 7:29 http://www.biomedcentral.com/1472-6882/7/29
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control. Also, MCE caused elevation of serum HDL-CH
levels (Table 3).
Discussion
Alloxan is known for its selective pancreatic islet β-cell
cytotoxicity and has been extensively used to induce dia-
betes mellitus in animals. In our present experimental
studies it was observed that MCE can reverse the meta-
bolic derangements occuring in alloxan induced diabetes
in rats.
To gain an understanding of the mechanism(s) by which
MCE elicits its hypoglycemic activity, various biochemical
parameters were evaluated following subchronic (30 day)
treatment in rats. Our experimental findings suggest a sig-
nificant reduction in i) blood glucose levels on different
days, ii) glycosylated hemoglobin levels and its HbA1c
fraction and iii) serum cholesterol and triglyceride levels
in both, MCE and glibenclamide treated rats. MCE and
glibenclamide elevated the reduced serum insulin, total
protein and liver glycogen levels. Glycosylated peptides
are elevated several fold in diabetes. Since the average life
span of a red blood cell is 120 days, the assumption of the
clinical importance of GHbA levels is that they represent
time-averaged values for blood glucose over the last or
next 3 to 4 month period. This provides a simple, useful
means of assessing treatment efficacy and patient compli-
ance. The increase in serum insulin levels suggested that
MCE like glibenclamide enhances the secretion of insulin
from the beta cells of the islets of Langerhans. Further, it
has an ability to restore the protein breakdown and
enhance the glycogenesis process in the liver of diabetic
rats. In addition, in vitro tests indicated that MCE and glib-
enclamide can induce stimulation of the glucose uptake
process by diaphragm and inhibition of the glycogenoly-
sis in liver of rats. Histopathological studies revealed that
MCE and glibenclamide significantly improved the histo-
logical architecture of the islets of Langerhans. The groups
treated with MCE (150 and 300 mg/kg) and glibencla-
mide (4 mg/kg) showed greater persistence of the islets of
Langerhans and lesser degree of necrotic changes as com-
pared to the untreated alloxan diabetic rats.
Hence, tentatively, it may be summarized that the possi-
ble mechanism(s) by which MCE brings about its antihy-
perglycemic action may be through potentiation of
pancreatic secretion of insulin from the intact β-cells of
islets (which was clearly evidenced by the increased level
of insulin in diabetic rats treated with MCE and glibencla-
mide) coupled with extra-pancreatic mechanisms like
decreased glycogenolysis and enhanced glycogenesis by
the liver and/or enhanced transport of blood glucose to
Table 2: Effect of Momordica charantia extract on liver glycogen levels, glucose uptake by hemidiaphragm and glycogenolysis by liver of 
alloxan diabetic rats
Oral treatment (n = 8) Liver glycogen g/100 g Glucose uptake by 
hemidiaphragm mg/
100 mg
Glucose transfer 
by liver mg/g
Pancreas histoarchetechture necrotic 
changes & persistence of islets of 
Langerhans*
Mean ± SEM
Normal control 3.8 ± 0.4 16.0 ± 0.4 26.9 ± 0.4 0.3 ± 0.01
Diabetic control 1.0 ± 0.2# 4.7 ± 0.2# 42.6 ± 2.2# 3.6 ± 0.13
MCE (150 mg/kg) 1.6 ± 0.2b 8.1 ± 0.3a 17.9 ± 0.4a 2.9 ± 0.2
MCE (300 mg/kg) 1.7 ± 0.1a 15.9 ± 0.4a 15.6 ± 0.7a 1.9 ± 0.12
Glibenclamide 4 mg/kg 1.8 ± 0.1a 14.0± 0.3a 17.9 ± 0.8a 1.8 ± 0.18
Significant difference of diabetic control from normal control: #P < 0.001
Significant difference of treated groups from diabetic control: aP < 0.001, bP < 0.005,
*Scoring system: 0 – Normal, 1 – very mild, 2 – mild, 3 – moderate, 4 – marked
Table 3: Effect of MCE on the serum lipids and blood glucose levels in old obese rats
Oral treatment 
(n = 8)
Cholesterol
(mg %)
HDL-CH (mg %) VLDL-CH (mg %) LDL-CH (mg %) Triglyceride 
(mg %)
Blood glucose 
(mg %)
Mean ± SEM
Normal control 80.8 ± 1.7 18.7 ± 0.9 8.4 ± 0. 54.4 ± 0.21 60.4 ± 0.39 68.8 ± 2.1
Obese control 115.9 ± 2.7b 27.8 ± 0.4a 24.6 ± 0.8b 64.4 ± 2.2a 123.2 ± 4.1b 116.5 ± 1.6b
MCE (150 mg/kg) 88.5 ± 1.7c 31.2 ± 0.6c 20.2 ± 0.9c 37.2 ± 2.0d 100.9 ± 4.4c 94.5 ± 1.1a
MCE (300 mg/kg) 81.6 ± 1.9d 32.4 ± 0.6d 17.8 ± 0.2d 26.3 ± 3.1d 88.7 ± 3.2d 77.1 ± 1.2d
Significant difference of Obese control from Normal control: aP < 0.05, bP < 0.01,
Significant difference of treatment groups from Obese control: cP < 0.01, dP < 0.001BMC Complementary and Alternative Medicine 2007, 7:29 http://www.biomedcentral.com/1472-6882/7/29
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peripheral tissues (as seen by the stimulatory effect on glu-
cose uptake in rat diaphragm). MCE's direct effect on the
regeneration of the islets of pancreas was also evidenced
by the restoration of the architecture of the islets of Lang-
erhans in histopathological studies. With such an evi-
dence, it is possible to assume that MCE might stimulate
the secretion of insulin from the beta cells by a mecha-
nism similar to that of oral hypoglycemic agents (like sul-
fonylureas) i.e. by depolarization of islet membrane
which consequently alters the change in ion flux [15] or
affecting receptors responsible for the recognition of insu-
lin secretagogues [16]. These mechanism(s) have been
accepted as a paradigm for the action of all insulin releas-
ing agents.
Hypercholesterolemia and hypertriglyceridemia have
been reported to occur in alloxan diabetic rats [17,18]. A
significant increase in serum cholesterol and triglycerides
observed in our experiment is in agreement with the find-
ings of the aforementioned authors. The marked hyperli-
pidemia that characterizes the diabetic state may therefore
be regarded as a consequence of the uninhibited actions
of lipolytic hormones on the fat depots [4]. MCE treat-
ment to old obese rats elicited a dose related hypolipi-
demic activity. All the lipid components viz cholesterol,
LDL-CH and triglycerides were reduced significantly. The
more prominent effect being reduction in LDL-CH which
is a known triggering factor for coronary occlusion or its
block. Similarly HDL-CH is a protective cholesterol and
responsible for transportation of cholesterol. Considering
MCE's effect on these lipid components, it can be
assumed a potential hypolipidemic agent, which will be a
great advantage both in diabetic condition as well as the
associated atherosclerosis or hyperlipidemic conditions.
The antihyperlipidaemic effect of MCE may be due to the
down regulation of NADPH and NADH cofactors in the
fat metabolism. MCE may exert its antilipidemic action by
oxidizing NADPH.
Conclusion
From our experimental findings it is possible to conclude
that MCE exhibited promising antidiabetic activity in
alloxan diabetic rats. Its antihyperlipidemic effect could
represent a protective mechanism against the develop-
ment of atherosclerosis, especially in diabetic condition.
Finally, it can be considered that MCE is safe for oral con-
sumption and elicits promising hypoglycemic activity in
animal experiments. Hence, it may be pursued for its clin-
ical usefulness in the management of diabetes mellitus
and other associated complications.
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